Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Threat To Global Medtech Markets Is Rising

Executive Summary

China’s economic might and industrial drive are being felt increasingly in medtech, and the just-released 14th five-year plan will give Chinese manufacturers more support for expansion, both at home and in overseas markets. Should EU and US industries be worried?

You may also be interested in...



China’s Medtech Market Trends: Six Of The Best For 2022

The key health care and infrastructure trends in China and how they will affect the local medtech market and industry are listed by Medtech Insight’s sister news portal, Omdia.

Medtechs Must Gear Up For New China Data Protection Rules

China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.

LinkDoc’s US Listing In Jeopardy Following China's New Data Security Requirements

The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT144339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel